Notably, in the subset of ALS defined as having innate immune dysfunction (elevated CRP), the median survival in the placebo group of 28.2 months was extended to 42.7 months in the NP001 treatment group and to 45.5 months in patients with low creatinine levels. This evidence concerns the gene CRP and amyotrophic lateral sclerosis.